EMJ Cardiology 10 [Supplement 1] . 2022

In an interview conducted by EMJ, a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for aficamten. A cardiac myosin inhibitor, aficamten targets the underlying pathophysiology of hypertrophic cardiomyopathy.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?